The epidemiological association of altitude with chronic kidney disease: Evidence of protective effect

Nephrology

Volumn 16, Issue 2, 2011, Pages 219-224

  Ghahramani, Nasrollah ^a   Ahmed, Faris ^a   Al Laham, Ammar ^b   Lengerich, Eugene J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Pinnacle Health System   (United States)

Author keywords

altitude; chronic kidney disease; erythropoietin; kidney; NHANES; USRDS

Indexed keywords

ADULT; ALTITUDE ACCLIMATIZATION; ARTICLE; DEMOGRAPHY; DISEASE ASSOCIATION; EPIDEMIOLOGY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RENAL PROTECTION;

ALTITUDE; DATABASES, FACTUAL; FEMALE; GLOMERULAR FILTRATION RATE; HEALTH SURVEYS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; PREVALENCE;

EID: 79551507646     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01332.x     Document Type: Article

References (26)

1. Nishiya D, Omura T, Shimada K, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J. Pharmacol. Sci. 2006; 101: 31-9.
2. Sanz AB, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A,. Mechanisms of renal apoptosis in health and disease. J. Am. Soc. Nephrol. 2008; 19: 1634-42.
3. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O,. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-85.
4. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK,. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol. Dial. Transplant. 2001; 16: 307-12.
5. Gonzalez AJ, Hernandez D, De Vera A, et al. ACE gene polymorphism and erythropoietin in endurance athletes at moderate altitude. Med. Sci. Sports Exerc. 2006; 38: 688-93.
6. Friedmann B, Frese F, Menold E, Kauper F, Jost J, Bartsch P,. Individual variation in the erythropoietic response to altitude training in elite junior swimmers. Br. J. Sports Med. 2005; 39: 148-53.
7. Ezzati TM, Massey JT, Wakesberg J, Chu A, Maurer KR,. Sample Design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2 1992; 113: 1-35.
8. Datasheeer, LLC: ZIP Code Database List. 2010 [Cited 16 Mar 2010.] Available from URL:.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999; 130: 461-70.
10. Botev R, Mallie JP, Couchoud C, et al. Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin. J. Am. Soc. Nephrol. 2009; 4: 899-906.
11. Mattman A, Eintracht S, Mock T, et al. Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging. J. Am. Soc. Nephrol. 2006; 17: 487-96.
12. USRDS. Researcher's Guide to the USRDS Database. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.
13. Rossert J, McClellan WM, Roger SD, Verbeelen DL,. Epoetin treatment: What are the arguments to expect a beneficial effect on renal disease progression? Nephrol. Dial. Transplant. 2002; 17: 359-62.
14. De Heer E, Sijpkens YW, Verkade M, et al. Morphometry of interstitial fibrosis. Nephrol. Dial. Transplant. 2000; 15 (Suppl 6): 72-3.
15. Norman JT, Clark IM, Garcia PL,. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int. 2000; 58: 2351-66.
16. Kasap B, Soylu A, Kuralay F, et al. Protective effect of Epo on oxidative renal injury in rats with cyclosporine nephrotoxicity. Pediatr. Nephrol. 2008; 23: 1991-99.
17. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M,. Antioxidative effects of erythropoietin. Kidney Int. Suppl. 2007; S10-S15.
18. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am. J. Kidney Dis. 1994; 24: 777-84.
19. Robach P, Fulla Y, Westerterp KR, Richalet JP,. Comparative response of EPO and soluble transferrin receptor at high altitude. Med. Sci. Sports Exerc. 2004; 36: 1493-8, discussion 92.
20. Windsor JS, Rodway GW,. Heights and haematology: The story of haemoglobin at altitude. Postgrad. Med. J. 2007; 83: 148-51.
21. Abbrecht PH, Littell JK,. Plasma erythropoietin in men and mice during acclimatization to different altitudes. J. Appl. Physiol. 1972; 32: 54-8.
22. Eckardt KU, Dittmer J, Neumann R, Bauer C, Kurtz A,. Decline of erythropoietin formation at continuous hypoxia is not due to feedback inhibition. Am. J. Physiol. 1990; 258: F1432-F1437.
23. Reynafarje C, Lozano R, Valdivieso J,. The polycythemia of high altitudes: Iron metabolism and related aspects. Blood 1959; 14: 433-55.
24. Brookhart MA, Schneeweiss S, Avorn J, et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J. Am. Soc. Nephrol. 2008; 19: 1389-95.
25. Wystrychowski G, Wystrychowski W, Zukowska-Szczechowska E, Tomaszewski M, Grzeszczak W,. Selected climatic variables and blood pressure in Central European patients with chronic renal failure on haemodialysis treatment. Blood Press. 2005; 14: 86-92.
26. Argiles A, Mourad G, Mion C,. Seasonal changes in blood pressure in patients with end-stage renal disease treated with hemodialysis. N. Engl. J. Med. 1998; 339: 1364-70.